Flagship’s AI unicorn Generate raises $273M Series C, as first drug in 17-program pipeline enters the clinic

Flagship Pioneering’s AI-focused startup Generate:Biomedicines has raised another megaround that will push multiple drug programs into the clinic.

The Somerville, MA-based biotech said Thursday it has closed a $273 million Series C round bringing in new investors, including Amgen and Nvidia’s venture capital arm. The cash will support a sprawling…
Click here to view original post